The Pathophysiology of Ovarian Hyperstimulation Syndrome (OHSS)

A Proposal Role of the Ovarian Derived Prorenin to Angiotensin Cascade (ODPAC)
  • Randy S. Morris
  • I. Lane Wong
  • Yung S. Do
  • Willa A. Hsueh
  • Rogerio A. Lobo
  • Mark V. Sauer
  • Richard J. Pauslon
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 377)


Despite the fact that it was first described over thirty years ago, the factors responsible for (OHSS) have continued to elude investigators. During this time, several theories have been popularized but none have become widely accepted. Recently, it has been suggested that angiotensin II (Ang II) derived from the ovary plays an important role in the development of OHSS (1). This paper will briefly review previous theories and present the results of experiments performed at the University of Southern California School of Medicine that add weight to the notion that ODPAC is involved in OHSS.


Follicular Fluid Zealand White Rabbit PCOS Patient Oocyte Donor Ovarian Hyperstimulation Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–261.PubMedGoogle Scholar
  2. 2.
    Golan A, Ronel R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation: An update review. Obstet Gynecol Surv. 1989; 44: 430–440.PubMedCrossRefGoogle Scholar
  3. 3.
    McClure N, Leya J, Radwanska E, Rawlins R, Haning RV. Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod. 1992; 7: 758–764.PubMedGoogle Scholar
  4. 4.
    Ferrareti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe hyperstimulation syndrome. Hum Reprod. 1992; 7: 180–183.Google Scholar
  5. 5.
    Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril. 1969; 20: 443–447.PubMedGoogle Scholar
  6. 6.
    Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril. 1978; 20: 443–448.Google Scholar
  7. 7.
    Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, David A, Serr DM, Salomy M. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet. 1965; ii: 1213–1215.CrossRefGoogle Scholar
  8. 8.
    Haning RV, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol. 1985; 66: 220–225.PubMedGoogle Scholar
  9. 9.
    Engel T, Jewelicz R, Dyrenfurth I, Speroff L, Vande Wiele RL. Ovarian hyperstimulation syndrome. Amer J Obstet Gynecol. 1972; 112: 1052–1060.Google Scholar
  10. 10.
    Davis JS. Hormonal control of plasma and erythrocyte volume of rat uterus. Amer J Physiol. 1960; 199: 841–846.PubMedGoogle Scholar
  11. 11.
    Miles RA, Lobo RA, Paulson RJ, Sauer MV. The use of testolactone to prevent ovarian hyperstimulation syndrome (OHSS) after gonadotropin therapy. Abstract. Presented at the th meeting of the Society for Gynecologic Investigation. 1992.Google Scholar
  12. 12.
    Hurwitz A, Krausz M, Eldar-Geva T, Yagel S, Schenker JG, Palti Z, Laufer N. Production of 6-keto-PGF1α in hyperstimulated cycles: In vivo and in vitro studies. Int J Fertil. 1991; 36: 252–256.PubMedGoogle Scholar
  13. 13.
    Armstrong DT, Grinwich DL. Blockade of spontaneous and LH-induced ovulation in rats by indomethacin, an inhibitor of prostaglandin biosynthesis. Prostaglandins. 1972; 1: 21–28.PubMedGoogle Scholar
  14. 14.
    Pride SM, Ho Yuen B, Moon YS, Leung PCS. Relationship og gonadotropin releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Amer J Obstet Gynecol. 1986; 154: 1155–1160.Google Scholar
  15. 15.
    Zaidise I, Friedman M, Lindenbaum ES, Askenazi R, Peretz BA, Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Europ J Obstet Gynecol Reprod Biol. 1983; 15: 55–60.CrossRefGoogle Scholar
  16. 16.
    Erlik Y, Naot Y, Friedman M, Ben-David E, Paldi E. Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol. 1979; 53: 580–582.PubMedGoogle Scholar
  17. 17.
    Szego CM, Gitin ES. Ovarian histamine depletion during acute hyperemic response to luteinizing hormone. Nature. 1964; 201:682.PubMedCrossRefGoogle Scholar
  18. 18.
    Knox GE. Antihistamine blockade of the ovarian hyperstimulation syndrome. Amer J Obstet Gynecol. 1974; 118: 992–994.Google Scholar
  19. 19.
    Loukides JA, Loy RA, Edwards R, Honig J, Visintin I, Polan ML. Human follicular fluids contain tissue macrophages. J Clin Endoc Metab. 1990; 71: 1363–1367.CrossRefGoogle Scholar
  20. 20.
    Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril. 1993; 60: 826–833.PubMedGoogle Scholar
  21. 21.
    Culler MD, Tarlatzis BC, Lightman A, Fernandez LA, DeCherney AH, Negro-Vilar A, Naftolin F. Angiotensin II-like immunoreactivity in human ovarian follicular fluid. J Clin Endoc Metab. 1986; 62: 613–615.CrossRefGoogle Scholar
  22. 22.
    Derkx FHM, Alberda AT, Zeilmaker GH, Schalekamp MADH. High concentrations of immunoreactive renin, prorenin, and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynecol. 1987; 94: 4–9.CrossRefGoogle Scholar
  23. 23.
    Itskovitz J, Rubattu S, Levron J, Sealey JE. Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. J Clin Endoc Metab. 1992; 75: 906–910.CrossRefGoogle Scholar
  24. 24.
    Bisset GS, Lewis GP. Spectrum of pharmacological activity in some biologically active peptides. Br J Pharmacol. 1962; 19: 168–182.Google Scholar
  25. 25.
    Robertson AL, Khairallah PA. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res. 1972; 31: 923–931.PubMedCrossRefGoogle Scholar
  26. 26.
    Morel NML, Petruzzo PP, Hechtman HB, Shepro D. Inflammatory agonists that increase microvascular permeability in vivo stimulate cultured pulmonary microvessel endothelial cell contraction. Inflammation. 1990; 14: 571–582.PubMedCrossRefGoogle Scholar
  27. 27.
    Franken AAM, Derkx FHM, Schalekamp MADH, Manint’Veld AJ, Hop WCJ, van Rens, EH, de Jong PTVM. Association of high plasma prorenin with diabetic nephropathy. J Hypert. 1988; 6s4:s461–s463.Google Scholar
  28. 28.
    Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graef Arch Clin Exper Opthalm. 1990; 228: 505–509.CrossRefGoogle Scholar
  29. 29.
    Ikeda T, Nakayama D, Gomi T, Sakurai J, Yamazaki T, Yuhara M. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron. 1989; 52: 72–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Ruilope LM, Miranda B, Oliet A, Millet VG, Rodicio JL, Romer JC, Raij L. Control of hypertension with the angiotesnin converting enzyme inhibitor captopril reduces glomerular proteinuria. J Hypert. 1988; 6s4:s467–s469.Google Scholar
  31. 31.
    Stornello M, Valvo EV, Puglia N, Scapellato L. Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypert. 1988; 6s4:s464–s466.Google Scholar
  32. 32.
    Navot D, Margoliath EJ, Laufer N, Birkinfeld A, Relou A, Rosier A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 1987; 48: 57–61.PubMedGoogle Scholar
  33. 33.
    Ong ACM, Eisen V, Rennie DP, Homburg R, Lachelin GCL, Jacobs HS, Slater JDH. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endoc. 1991; 34: 43–49.CrossRefGoogle Scholar
  34. 34.
    Morris RS, Wong IL, Hatch IE, Paulson RJ, Lobo RA. Prorenin is elevated in PCO and may reflect hyperandrogensim. Abstract presented at the XXth meeting of the Society for Gynecologic Investigation. Chicago, IL. March 1994. Submitted to the J of the Soc Gyn Invest.Google Scholar
  35. 35.
    Morris RS, Wong IL, Gentschein E, Sauer MV, Lobo RA, and Paulson RJ. Angiotensin converting enzyme inhibition for the prevention of ovarian hyperstimulation syndrome: A randomized prospective, placebo controlled double blind trial. Abstract presented at the th meeting of the Pacific Coast Fertility Society, Indian Wells, CA April 19–23, 1994. Submitted to Hum Reprod.Google Scholar
  36. 36.
    Morris RS, Wong IL, Paulson RJ. Angiotensin converting enzyme inhibition in the gonadotropin stimulated rabbit: effect on estradiol production. Submitted to Fertil Steril.Google Scholar
  37. 37.
    Morris RS, Lindheim SR, Paulson RJ, McConnel RA, Sauer MV. Angiotensin converting enzyme inhibition dramatically reverses lutealphase steroid production in oocyte donors. Abstract presented at the 38th Annual meeting of the American Fertility Society. Montreal, Canada, March 1994. Submitted to Fertil Steril.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Randy S. Morris
    • 1
  • I. Lane Wong
    • 1
  • Yung S. Do
    • 2
  • Willa A. Hsueh
    • 2
  • Rogerio A. Lobo
    • 1
  • Mark V. Sauer
    • 1
  • Richard J. Pauslon
    • 1
  1. 1.Division of Reproductive EndocrinologyUniversity of Southern California School of Medicine, Los Angleles County Women’s and Children’s HospitalLos AngelesUSA
  2. 2.Department of MedicineUniversity of Southern California School of Medicine, Los Angleles County Women’s and Children’s HospitalLos AngelesUSA

Personalised recommendations